Ventripoint Diagnostics got the green-light from European regulators to launch the NRV 2D ultrasound imaging application on its VMS right-heart analysis platform, which allows clinicians to assess heart imaging in patients with additional cardiac conditions.
The NRV application allows clinicians to assess the right ventricle in patients that may also have left-heart failure, valve disease or other conditions, as long as they do not have significant congenital heart defects or pulmonary hypertension, according to Ventripoint
The NRV database expands the VMS-2DE heart analysis system, allowing physicians to "examine almost every patient they see," said CEO George Adams in prepared remarks. The company further expects that the new application may be used to provide a baseline study for at-risk patients.
The Seattle, Wash.-based diagnostic device company also recently passed the annual audit needed to continue to sell devices in Europe and Canada. The VMS system is approved only for investigational use in the U.S.
Last year, the company announced CE Mark for pulmonary arterial hypertension application.